Search Results - "Deodhar, Atul A"

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies by Deodhar, Atul A., Miceli‐Richard, Corine, Baraliakos, Xenofon, Marzo‐Ortega, Helena, Gladman, Dafna D., Blanco, Ricardo, Das Gupta, Ayan, Martin, Ruvie, Safi, Jorge, Porter, Brian, Shete, Abhijit, Rosenbaum, James T.

“…Objective The objective of this study was to report the incidence of uveitis in secukinumab‐treated patients with ankylosing spondylitis (AS) in a pooled…”
Get full text

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results by Deodhar, Atul A., Mease, Philip J., Rahman, Proton, Navarro-Compán, Victoria, Strand, Vibeke, Hunter, Theresa, Bolce, Rebecca, Leon, Luis, Lauzon, Steve, Marzo-Ortega, Helena

“…BACKGROUNDThis analysis assessed improvements in patients with radiographic axial spondyloarthritis (r-axSpA) treated with ixekizumab in the Assessment of…”
Get full text

Growth Hormone Perturbations in Fibromyalgia: A Review by Jones, Kim D., PhD, Deodhar, Parimal, Lorentzen, Ashley, Bennett, Robert M., MD, Deodhar, Atul A., MD

“…Objective Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue, disrupted sleep, depression, and physical deconditioning. In this…”
Get full text

Axial spondyloarthritis classification criteria: the debate continues by Dubreuil, Maureen, Deodhar, Atul A

“…The Assessment of Spondyloarthritis International Society (ASAS) axial spondyloarthritis (axSpA) classification criteria marked a major step forward in SpA…”
Get full text

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials by Schreiber, Stefan, Colombel, Jean-Frederic, Feagan, Brian G, Reich, Kristian, Deodhar, Atul A, McInnes, Iain B, Porter, Brian, Das Gupta, Ayan, Pricop, Luminita, Fox, Todd

“…Here, we present the reported incidence rates of inflammatory bowel disease (IBD) in patients receiving treatment with secukinumab for psoriasis (PsO),…”
Get more information

Complementary medicine for axial spondyloarthritis: is there any scientific evidence? by Danve, Abhijeet, Deodhar, Atul A

“…PURPOSE OF REVIEWMajority of patients with axial spondyloarthritis (axSpA) report use of complementary and alternative medicine (CAM) therapies before and even…”
Get full text

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group by Maksymowych, Walter P, Lambert, Robert Gw, Østergaard, Mikkel, Pedersen, Susanne Juhl, Machado, Pedro M, Weber, Ulrich, Bennett, Alexander N, Braun, Juergen, Burgos-Vargas, Ruben, de Hooge, Manouk, Deodhar, Atul A, Eshed, Iris, Jurik, Anne Grethe, Hermann, Kay-Geert Armin, Landewé, Robert Bm, Marzo-Ortega, Helena, Navarro-Compán, Victoria, Poddubnyy, Denis, Reijnierse, Monique, Rudwaleit, Martin, Sieper, Joachim, Van den Bosch, Filip E, van der Heijde, Désirée, van der Horst-Bruinsma, Irene E, Wichuk, Stephanie, Baraliakos, Xenofon

“…The Assessment of SpondyloArthritis international Society (ASAS) MRI working group (WG) was convened to generate a consensus update on standardised definitions…”
Get more information

The field of spondyloarthritis coming of age by Deodhar, Atul A

Get full text

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis by Elewski, Boni E, Baddley, John W, Deodhar, Atul A, Magrey, Marina, Rich, Phoebe A, Soriano, Enrique R, Soung, Jennifer, Bao, Weibin, Keininger, Dorothy, Marfo, Kwaku, Patekar, Manmath, Sharma, Abhishek, Shete, Abhijit, Lebwohl, Mark Gabriel

“…Approximately one-quarter of the global population have latent tuberculosis infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million…”
Get more information

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1) by Deodhar, Atul A., Dougados, Maxime, Baeten, Dominique L., Cheng‐Chung Wei, James, Geusens, Piet, Readie, Aimee, Richards, Hanno B., Martin, Ruvie, Porter, Brian

“…Objective To evaluate the effect of secukinumab (interleukin‐17A inhibitor) on patient‐reported outcomes in patients with active ankylosing spondylitis (AS)…”
Get full text

Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial by Baraliakos, Xenofon, Kivitz, Alan J, Deodhar, Atul A, Braun, Jürgen, Wei, James C, Delicha, Eumorphia Maria, Talloczy, Zsolt, Porter, Brian

“…Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over…”
Get full text

Advances in spondyloarthritis: glimpse in the future by Deodhar, Atul A

Get full text

Traumatic spondyloptosis resulting from high-energy trauma concurrent with a tonic-clonic seizure by Daniels, Alan H., BA, Deodhar, Atul A., MD, Hart, Robert A., MD

“…Abstract Background context Traumatic lumbosacral dislocation injuries are rare, high-energy injuries that are challenging to surgically manage. Purpose To…”
Get full text

Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis by Rosenzweig, Holly L, Vance, Emily E, Asare-Konadu, Kofi, Koney, Kylie V, Lee, Ellen J, Deodhar, Atul A, Sen, Rouhin, Caplan, Liron, Napier, Ruth J

“…Polymorphisms in the antifungal signalling molecule are associated with ankylosing spondylitis (AS). Here, we investigated the cellular mechanism by which…”
Get more information

Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Gladman, Dafna D, Mease, Philip J, Bird, Paul, Soriano, Enrique R, Chakravarty, Soumya D, Shawi, May, Lavie, Frederic, Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S, Kavanaugh, Arthur, Deodhar, Atul A, Østergaard, Mikkel, Baraliakos, Xenofon

Get more information

Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping Review by Tran, Kim A, Harrod, Curtis, Bourdette, Dennis N, Cohen, David M, Deodhar, Atul A, Hartung, Daniel M

“…Repository corticotropin injection is an expensive medication that was approved in 1952 for the treatment of many inflammatory conditions. The clinical…”
Get more information

Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for development by Deodhar, Atul A, Kumthekar, Anand, Dubreuil, Maureen

“…Axial spondyloarthritis (axSpA) is a chronic inflammatory condition with articular and extra-articular manifestations. Remission, a state of absence of…”
Get full text

Entheses and Bones in Spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN) by COLBERT, Robert A, DEODHAR, Atul A, FOX, David, GRAVALLESE, Ellen M, KHAN, Muhammad Asim, MCGONAGLE, Dennis, REVEILLE, John D, SCHETT, GEORG, WEISMAN, Michael, CLEGG, Daniel O

“…The Spondyloarthritis Research and Therapy Network (SPARTAN), founded in 2003 to promote research, education, and treatment of ankylosing spondylitis (AS) and…”
Get full text

A combination of 6 months of treatment with pyridostigmine and triweekly exercise fails to improve insulin-like growth factor-I levels in fibromyalgia, despite improvement in the acute growth hormone response to exercise by JONES, Kim Dupree, DEODHAR, Atul A, BURCKHARDT, Carol S, PERRIN, Nancy A, HANSON, Ginger C, BENNETT, Robert M

“…OBJECTIVE: People with fibromyalgia (FM) often have low insulin-like growth factor-I (IGF-I) levels and a suboptimal growth hormone (GH) response to acute…”
Get full text

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study by Deodhar, Atul A., Shiff, Natalie J., Gong, Cinty, Hsia, Elizabeth C., Lo, Kim Hung, Kim, Lilliane, Xu, Stephen, Reveille, John D.

“…This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late…”
Get full text